

Vitae Pharmaceuticals, Inc. (VTAE)

Downgrading to Market Perform Due to Disappointing Top-Line Results in Diabetes

MARKET DATA

Price	\$15.19
52-Week Range:	\$5.41 - \$23.35
Shares Out. (M):	21.8
Market Cap (\$M):	\$331.1
Average Daily Vol. (000):	204.0
Cash (M):	\$79
Cash/Share:	\$3.60
Enterprise Value (M):	\$260
Float (M):	20.4
LT Debt (M):	\$0

Source: Thomson Reuters and JMP Securities LLC

MARKET PERFORM | Price: \$15.19 | Target Price: N/A

INVESTMENT HIGHLIGHTS

Vitae Pharmaceuticals announced that VTP-34072 did not meet its partner's efficacy criteria; downgrading to Market Perform from Market Outperform and removing our \$16 price target. Vitae announced that top-line results of the metformin combination treatment arm of VTP-34072 did not meet the efficacy expectations of partner Boehringer Ingelheim. While the company expects top-line results for monotherapy in 2H15, we are not encouraged with the inability of VTP-34072 to hit a convincing clinical threshold; therefore, we are removing the contribution of VTP-34072 from our model. While the company also announced the initiation of clinical trials today for VTP-43742, a preclinical ROR- γ t inhibitor in development for autoimmune disease, in Phase I safety and tolerability studies, efficacy results are not expected until the end of 2015, leaving few value-driving catalysts in the interim, in our view. We remind investors that the preclinical data supporting advancement of VTP-43742 are compelling, but we currently do not ascribe value to the program. We hope to revisit the potential to incorporate the contribution of VTP-43742, the company's wholly owned preclinical asset for the treatment of autoimmune diseases, including psoriasis, at a later date; but at present, we believe the market fairly values the platform, including assets currently in development.

Changes to our model. We present changes to our estimates in Figure 2 that primarily reflect the removal of milestone contributions from the VTP-34072 program in the near term.

Vitae is an early stage, drug discovery and development company that uses its proprietary CONTOUR structure-based drug design platform for the development of therapeutic candidates directed against validated targets that are difficult to drug. While Vitae's programs are early stage, its Alzheimer's drug BI 1147560 has been validated scientifically and de-risked financially via a business development agreement with German biopharmaceutical company, Boehringer Ingelheim (private). The CONTOUR platform continues to develop small molecules with class-defining biochemical efficacy, and read-outs expected at year-end 2015 and in 1H16 for several important pipeline assets, including VTP-43742 safety data in 2H15 and efficacy data in psoriasis at EOY and results from Phase I studies of BI 1147560 in 1H16.

FY DEC		2014A	2015E	2016E
Revenue (\$M)	1Q	--	\$0.2A	--
	2Q	--	\$0.0	--
	3Q	\$6.2	\$0.0	--
	4Q	\$0.2	\$7.0	--
	FY	\$8.7	\$7.0	\$0.0
EPS	1Q	--	(\$0.47)A	--
	2Q	--	(\$0.50)	--
	3Q	(\$1.04)	(\$0.52)	--
	4Q	(\$0.40)	(\$0.22)	--
	FY	(\$3.61)	(\$1.70)	(\$2.14)
Previous FY		NC	NC	(\$1.76)

Source: Company reports and JMP Securities LLC

STOCK PRICE PERFORMANCE



FIGURE 1. Upcoming Catalysts

Timing	Program	Catalyst
mid-15	VTP-43742 (RORyt)	Complete Phase I proof-of-concept safety and PK trial in healthy volunteers
2H15	VTP-34072	Phase II top-line results expected in type-2 diabetes monotherapy
2H15	VTP-43742 (RORyt)	Initiation of a multiple ascending dose Phase I in psoriatic patients
2H15	VTP-43742 (RORyt)	Completion of multiple ascending dose Phase I in psoriatic patients
2H15	VTP-38543 (LXRβ)	Initiate Phase I safety and PK trial clinical trial
2H15	BI 1147560 (BACE)	Initiate Phase I clinical trial
2016	VTP-38543 (LXRβ)	Results from Phase I trial in atopic dermatitis
2016	VTP-38443 (LXRβ)	File IND/ Initiate Phase I clinical trial in acute coronary syndrome
2016	VTP-43742 (RORyt)	Initiate Phase II trial (large indication)
2016	VTP-43742 (RORyt)	Initiate Phase II trial (rare/orphan indication)

Source: Company Presentations

FIGURE 2. Changes to Our Model

Vitae Pharmaceuticals (VTAE) (\$ MM)	2Q15E		3Q15E		4Q15E		FY 2015E		FY 2016E	
	Old	New	Old	New	Old	New	Old	New	Old	New
License revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2
Milestone revenue	0.0	0.0	0.0	0.0	7.0	7.0	7.0	7.0	0.0	0.0
Other										
Total Revenues	0.0	0.0	0.0	0.0	0.0	0.0	7.0	7.00	0.2	0.15
COGS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit	-	0.0	-	0.0	7.00	7.0	7.15	7.15	10.00	-
Operating Expenses	10.5	10.5	11.1	11.1	11.7	11.7	42.9	42.9	55.5	55.5
Research and development	7.9	7.9	8.3	8.3	8.7	8.7	32.4	32.4	42.5	42.5
General and administrative	2.6	2.6	2.8	2.8	3.0	3.0	10.5	10.5	13.0	13.0
Operating income (loss)	(10.5)	(10.5)	(11.1)	(11.1)	(4.7)	(4.7)	(35.7)	(35.7)	(45.5)	(55.5)
Other income (expense)	0.1	0.1	0.1	0.1	0.1	0.1	(0.3)	(0.3)	0.0	0.05
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	(0.1)	(0.1)	0.0	-
Pretax income	(10.4)	(10.4)	(11.0)	(11.0)	(4.6)	(4.6)	(36.0)	(36.0)	(45.5)	(55.5)
Net income	(10.4)	(10.4)	(11.0)	(11.0)	(4.6)	(4.6)	(35.8)	(35.8)	(45.5)	(55.5)
Basic EPS	(\$0.50)	\$ (0.50)	(\$0.52)	\$ (0.52)	(\$0.22)	\$ (0.22)	(\$1.70)	\$ (1.70)	(\$1.76)	\$ (2.14)
Diluted EPS	(\$0.50)	\$ (0.50)	(\$0.52)	\$ (0.52)	(\$0.22)	\$ (0.22)	(\$1.70)	\$ (1.70)	(\$1.76)	\$ (2.14)
Basic shares outstanding	20.93	20.93	21.04	21.04	21.14	21.14	20.98	20.98	25.89	25.89
Diluted shares outstanding	20.93	20.93	21.04	21.04	21.14	21.14	20.98	20.98	25.89	25.89

Source: JMP Securities LLC

FIGURE 3. Income Statement

Vitae Pharmaceuticals (VTAE)					2015E				2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E
Income Statement (\$MM)					1Q15A	2Q15E	3Q15E	4Q15E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E
Total Product Sales and Royalties									0.0	0.0	0.0	0.0	0.0	0.0	38.4	196.3	345.8	536.1	751.1
Collaborative Revenue					0.2														
Milestone Revenue						0.0	0.0	7.0	7.0	0.0	10.0	26.0	0.0	20.0	60.0	80.0	75.0	0.0	60.0
Total Revenue					0.2	0.0	0.0	7.0	7.0	0.0	10.0	26.0	0.0	20.0	98.4	276.3	420.8	536.1	811.1
Cost of Goods Sold										0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit					0.2	0.0	0.0	7.0	7.2	0.0	10.0	26.0	0.0	20.0	98.4	276.3	420.8	536.1	811.1
Operating Expenses:																			
Research and Development					7.5	7.9	8.3	8.7	32.4	42.5	53.1	61.1	67.2	84.0	107.5	123.7	142.2	163.5	188.1
% Growth					5.0%	5.0%	5.0%	5.0%	67.6%	85.0%	25.0%	15.0%	10.0%	25.0%	28.0%	15.0%	15.0%	15.0%	15.0%
% Total US Net Sales												#DIV/0!	#DIV/0!	#DIV/0!	15%	63%	41%	31%	25%
General and administrative					2.1	2.6	2.8	3.0	10.5	13.0	19.5	26.3	30.3	37.8	60.5	84.8	118.7	160.2	216.3
% Growth									20.0%	20.0%	50.0%	35.0%	15.0%	25.0%	60.0%	40.0%	40.0%	35.0%	35.0%
% Total US Net Sales												#DIV/0!	#DIV/0!	#DIV/0!	158%	43%	34%	30%	29%
Total operating expenses					9.6	10.5	11.1	11.7	42.9	55.5	72.6	87.4	97.5	121.8	168.1	208.4	260.9	323.7	404.3
Operating income (loss)					(9.5)	(10.5)	(11.1)	(4.7)	(35.7)	(55.5)	(62.6)	(61.4)	(97.5)	(101.8)	(69.7)	67.9	160.0	212.3	406.7
Other income (expense):																			
Interest income					0.1	0.1	0.1	0.1	0.0	0.0	0.7	0.0	(0.6)	(1.5)	(2.3)	(2.8)	(2.4)	(1.4)	0.0
Interest expense					(0.11)				(0.11)										
Loss on debt extinguishment					(0.21)				(0.21)										
Other income									-										
Total other income, net					(0.2)	0.1	0.1	0.1	(0.3)	0.0	0.7	0.0	(0.6)	(1.5)	(2.3)	(2.8)	(2.4)	(1.4)	0.0
Pretax income (loss)					(9.7)	(10.4)	(11.0)	(4.6)	(35.8)	(55.5)	(62.0)	(61.4)	(98.0)	(103.4)	(72.0)	65.1	157.6	210.9	406.7
Income tax benefit (provision)									0.0	0.0	0.0	0.0	0.0	27.1	21.6	(22.8)	(55.2)	(73.8)	(142.4)
Tax Rate									0%	0%	0%	0%	0%	26%	30%	35%	35%	35%	35%
Comprehensive income (loss)					(9.7)	(10.4)	(11.0)	(4.6)	(35.8)	(55.5)	(62.0)	(61.4)	(98.0)	(76.3)	(50.4)	42.3	102.4	137.1	264.4
Accretion of redeemable convertible preferred stock																			
Net income (loss) attributable to common stockholder					(9.7)	(10.4)	(11.0)	(4.6)	(35.8)	(55.5)	(62.0)	(61.4)	(98.0)	(76.3)	(50.4)	42.3	102.4	137	264
Basic EPS to common stockholder					\$ (0.47)	\$ (0.50)	\$ (0.52)	\$ (0.22)	\$ (1.70)	\$ (2.14)	\$ (2.36)	\$ (2.31)	\$ (3.65)	\$ (2.8)	\$ (1.8)	\$ 1.5	\$ 3.6	\$ 4.8	\$ 9.2
Diluted EPS to common stockholder					\$ (0.47)	\$ (0.50)	\$ (0.52)	\$ (0.22)	\$ (1.70)	\$ (2.14)	\$ (2.36)	\$ (2.31)	\$ (3.65)	\$ (2.8)	\$ (1.8)	\$ 1.5	\$ 3.6	\$ 4.7	\$ 9.0
Basic shares outstanding					20.8	20.9	21.0	21.1	21.0	25.9	26.2	26.5	26.8	27.2	27.5	27.8	28.1	28.5	28.8
Diluted shares outstanding					20.8	20.9	21.0	21.1	21.0	25.9	26.2	26.5	26.8	27.2	27.5	28.4	28.7	29.1	29.4

Source: JMP Securities LLC, Company filings

Company Description

Vitae is a biotechnology company focused on leveraging a discovery and development platform for the advancement of small molecule drugs to treat important unmet clinical diseases. Utilizing the company's proprietary Contour structure based discovery platform, Vitae is able to rapidly discover novel lead molecules with desired target efficacy and biological stability that support significant derisking at very early stages of drug development. Vitae has initially focused its development on two targets that treat large patient markets: type-2 diabetes and Alzheimer's disease. The company's most advanced clinical asset is VTP-34072, an inhibitor of 11- β HSD1, a preclinically validated target in diabetes and metabolic disease that is currently in Phase II clinical trials. Data is expected from this trial in the second half of 2015.

The second asset, BI 1147560, is an inhibitor of BACE-1, a target of high interest in the treatment of Alzheimer's disease that will enter Phase I clinical trials with expected biomarker and data read-outs by the beginning of 2016. Both of these clinical candidates target large markets and have been partnered since discovery for further development by Boehringer Ingelheim GmbH, resulting in significant upfront and milestone payments totaling \$152.4MM. The company has also used its platform to develop preclinical candidate inhibitors against difficult-to-target pathways in autoimmune disease, cardiovascular disease, and dermatological conditions. These wholly owned assets include VTP-43742, a ROR- γ t inhibitor strongly implicated in autoimmune diseases such as multiple sclerosis, psoriasis, and rheumatoid arthritis. Additionally, the company has developed VTP-38443 for the treatment of acute coronary syndrome, and VTP-38543 for the treatment of atopic dermatitis, both of which stimulate the LXR β receptor. Vitae is also developing an as-yet unnamed program to develop preclinical compounds for immunoncology applications.

Investment Risks

Potential risks to our investment thesis and price target include, but are not limited to:

Clinical and regulatory. If either VTP-34072 in diabetes or VTP-37948 in Alzheimer's is not able to meet any of its primary outcomes or suffer from safety and tolerability issues, Vitae and Boehringer Ingelheim (BI) may choose to end development in any of its current indications. Additionally, if the FDA and EMEA do not approve VTP-34072 or VTP-37948, Vitae's stock price would likely suffer.

Partnering. Vitae has partnered with (BI) in the development of VTP-34072 in diabetes and BI 1147560 in Alzheimer's. BI is responsible for the continued clinical and commercial development of both candidates and may decide to end development for one or more indications. If it were necessary for Vitae to develop and market any of its programs due to the loss or inability to retain a partner, it may be difficult to develop an internal commercial structure. Management has limited experience in commercial and marketing activities.

Competitive. The diabetes market is crowded and saturated with low-cost generic manufacturers of metformin and sulfonylureas. It may be difficult for BI and Vitae to garner significant market share. The high bar for safety and efficacy differentiation for the diabetes primary care market may limit adoption. BI 1147560 is not the only BACE-1 inhibitor in development and will not be a first-in-class therapy if Merck/Ligand are successful in bringing their drug to market. It may be difficult to compete in a market dominated by these therapies.

Financial. Vitae currently derives revenue from research and development funding and from license or collaboration agreements. The company sold ~6,875,000 shares in September 2014, raising net proceeds of ~\$51.15MM. We expect this funding to be able to carry it through to 2016. Like most non-profitable biotechnology companies, VTAE will likely need to seek additional financing, exposing current investors to dilutive risk.

JMP FACTS AND DISCLOSURES

Analyst Certification:

The research analyst(s) who prepared this report does/do hereby certify that the views presented in this report are in accordance with my/our personal views on the securities and issuers discussed in this report. As mandated by SEC Regulation AC no part of my/our compensation was, is or will be directly or indirectly related to the specific views or recommendations expressed herein. This certification is made under the obligations set forth in SEC Regulation AC. Any other person or entity may not use it for any other purpose. This certification is made based on my/our analysis on the date of this report's publication. I/We assume no obligation to update this certification to reflect any facts, circumstances or events that may subsequently come to my/our attention. Signed Michael G. King

JMP Securities Disclosures:

JMP Securities currently makes a market in the security of Vitae Pharmaceuticals, Inc.

JMP Securities was manager or co-manager of a public offering of securities for Vitae Pharmaceuticals, Inc. (VTAE) in the past 12 months, and received compensation for doing so.

JMP Securities expects to receive OR intends to seek compensation for investment banking services from Vitae Pharmaceuticals, Inc. in the next 3 months.

JMP Securities Investment Opinion Definitions:

Market Outperform (MO): JMP Securities expects the stock price to outperform relevant market indices over the next 12 months.

Market Perform (MP): JMP Securities expects the stock price to perform in line with relevant market indices over the next 12 months.


Market Underperform (MU): JMP Securities expects the stock price to underperform relevant market indices over the next 12 months.

JMP Securities Research Ratings and Investment Banking Services: (as of June 29, 2015)

JMP Rating	Regulatory Equivalent	# Co's Under Coverage	% of Total	# Co's Receiving IB Services in Past 12 Months				
				Regulatory Equivalent	# Co's Under Coverage	% of Total	% of Co's With This Rating	
MARKET OUTPERFORM	Buy	279	62.28%	Buy	279	62.28%	90	32.26%
MARKET PERFORM	Hold	140	31.25%	Hold	140	31.25%	16	11.43%
MARKET UNDERPERFORM	Sell	8	1.79%	Sell	8	1.79%	0	0%
COVERAGE IN TRANSITION		21	4.69%		21	4.69%	4	19.05%
TOTAL:		448	100%		448	100%	110	24.55%

Stock Price Chart of Rating and Target Price Changes:

Note: First annotation denotes initiation of coverage or 3 years, whichever is shorter. If no target price is listed, then the target price is N/A. In accordance with NASD Rule 2711, the chart(s) below reflect(s) price range and any changes to the rating or price target as of the end of the most recent calendar quarter. The action reflected in this note is not annotated in the stock price chart. Source: JMP Securities.



JMP Disclaimer:

JMP Securities LLC (the "Firm") compensates research analysts, like other Firm employees, based on the Firm's profitability, which includes revenues from the Firm's institutional sales, trading, and investment banking departments as well as on the quality of the services and activities performed that are intended to benefit the Firm's institutional clients. These data have been prepared by JMP Securities LLC for informational purposes only and are based on information available to the public from sources that we believe to be reliable, but we do not guarantee their accuracy or completeness. Any opinions and projections expressed herein reflect our judgment at this date and are subject to change without notice. These data are neither intended nor should be considered as an offer to sell or a solicitation or a basis for any contract for the purchase of any security or other financial product. JMP Securities LLC, its affiliates, JMP Group LLC, Harvest Capital Strategies LLC, and their respective partners, directors, officers, and associates may have a long or short position in, may act as a market maker for, or may purchase or sell a position in the securities mentioned herein. JMP Securities LLC or its affiliates may be performing, have performed, or seek to perform investment banking, advisory, or other services and may have acted as manager or co-manager for a public offering of securities for any company mentioned herein. The reader should assume that JMP Securities LLC will solicit business from the company covered in this report. Members of our Sales and Trading Department provide oral and/or written market opinions and trading strategies to our clients that reflect their personal opinions about stocks that are the subject of the firm's research reports. Our research analysts discuss trading strategies with clients that sometimes reflect short-term expectations for the price of the securities that are the subject of research reports. These trading strategies are distinct from the analysts' fundamental rating for the stock, which is based upon the analysts' view compared to other stocks under coverage for the relevant time period. © Copyright 2015. All rights reserved by JMP Securities LLC. JMP Securities LLC is a member of FINRA, NASDAQ, and SIPC.

Jeffrey H. Spurr
Director of Research
(415) 835-3903

RESEARCH PROFESSIONALS

FINANCIAL SERVICES

Alternative Asset Managers

Devin Ryan	(212) 906-3578
Brian McKenna	(212) 906-3545

Commercial & Specialty Finance

Christopher York	(415) 835-8965
Andrius Ellner	(415) 835-8962

Consumer Finance

David M. Scharf	(415) 835-8942
Douglas Greiner	(212) 906-3525

Financial Processing & Outsourcing

David M. Scharf	(415) 835-8942
Douglas Greiner	(212) 906-3525

Insurance

Matthew J. Carletti	(312) 768-1784
Christine Worley	(312) 768-1786
Solomon Mindlin	(212) 768-1788

Investment Banks & Brokers

Devin Ryan	(212) 906-3578
Brian McKenna	(212) 906-3545

Mortgage Operating Companies

REITs: Agency, Hybrid, & Commercial Mortgage

Steven C. DeLaney	(404) 848-7773
Trevor Cranston, CFA	(415) 869-4431
Charter Robinson	(757) 613-8955
Benjamin Zucker	(212) 906-3529

HEALTHCARE

Animal Health

J. T. Haresco, III, PhD	(415) 869-4477
-------------------------	----------------

Biotechnology

Liisa A. Bayko	(312) 768-1785
Masha Chapman	(415) 835-8944
Bhumika Sharma, PhD	(312) 768-1795
Jason N. Butler, PhD	(212) 906-3505
Harry Jenq, PhD	(212) 906-3509
Nazibur Rahman	(212) 906-3519
Michael G. King, Jr.	(212) 906-3520
Bryan Czyzewski, PhD	(212) 906-3577
Eric Ekland	(212) 906-3540
Naureen Quibria, PhD	(212) 906-3514

Healthcare Services & Facilities

Peter L. Martin, CFA	(415) 835-8904
Aaron Hecht	(415) 835-3963
Brian Riley	(415) 835-8908

Life Science Tools & Diagnostics

J. T. Haresco, III, PhD	(415) 869-4477
-------------------------	----------------

Medical Devices & Supplies

David Turkaly	(212) 906-3563
John Gillings	(212) 906-3564

Specialty Pharmaceuticals

REAL ESTATE

Housing & Land Development

Peter L. Martin, CFA	(415) 835-8904
Aaron Hecht	(415) 835-3963
Bharathwajan Iyengar	(415) 835-3902

Lodging & Leisure

Robert A. LaFleur	(212) 906-3510
Whitney Stevenson	(212) 906-3538

Property Services

Mitch Germain	(212) 906-3546
Peter Lunenburg	(212) 906-3537

REITs: Healthcare, Residential, & Specialty

Peter L. Martin, CFA	(415) 835-8904
Aaron Hecht	(415) 835-3963
Brian Riley	(415) 835-8908

REITs: Office, Industrial, & Diversified

Mitch Germain	(212) 906-3546
Peter Lunenburg	(212) 906-3537

Residential Services

Peter L. Martin, CFA	(415) 835-8904
Aaron Hecht	(415) 835-3963
Bharathwajan Iyengar	(415) 835-3902

TECHNOLOGY

Internet Security & Communications Infrastructure

Erik Suppiger	(415) 835-3918
John Lucia	(415) 835-3920

Internet & Digital Media

Ronald V. Josey III	(212) 906-3528
Ignatius Njoku	(415) 835-8960
Andrew Boone, CFA	(415) 835-3957
Shweta Khajuria	(415) 835-8916

Software

Patrick Walravens	(415) 835-8943
Peter Lowry	(415) 869-4418
Mathew Spencer	(415) 835-8930
Greg McDowell	(415) 835-3934
Rishi Jaluria	(415) 835-3961

Wireless & Cloud Computing Technologies

Alex Gauna	(415) 835-8998
------------	----------------

ADDITIONAL CONTACTS

Thomas R. Wright
Director of Equities
(212) 906-3599

Thomas Healy
Head of Institutional Sales
(212) 906-3533

600 Montgomery Street, Suite 1100
San Francisco, CA 94111
www.jmpsecurities.com